(Q35911236)

11 August 2017

0 references

1 reference

title

Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis (English)

1 reference

11 August 2017

1 reference

1 reference

1 reference

Xiaoyan Zhong

1

1 reference

11 August 2017

Dan Lai

2

1 reference

11 August 2017

Yun Ye

3

1 reference

11 August 2017

Xuping Yang

4

1 reference

11 August 2017

Bin Yu

5

1 reference

11 August 2017

Yilan Huang

6

1 reference

11 August 2017

language of work or name

1 reference

1 February 2016

1 reference

European Journal of Clinical Pharmacology

11 August 2017

1 reference

11 August 2017

72

1 reference

11 August 2017

6

1 reference

11 August 2017

655-663

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-016-2010-8

11 August 2017

0 references

cites work

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

GRADE guidelines: 7. Rating the quality of evidence--inconsistency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Insulin resistance in type 2 diabetes: association with truncal obesity, impaired fitness, and atypical malonyl coenzyme A regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Empagliflozin in the treatment of type 2 diabetes: evidence to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Empagliflozin: a review of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-016-2010-8

Empagliflozin as add-on to metformin in people with Type 2 diabetes

21 January 2018

1 reference

12 December 2020

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

1 reference

12 December 2020

Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial

1 reference

12 December 2020

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin

1 reference

12 December 2020

10.1007/S00228-016-2010-8

Identifiers

DOI

1 reference

11 August 2017

1 reference